Precigen, Inc. (I5X.F)

Compare

1.6450

+0.0720

+(4.58%)

At close: March 3 at 4:22:34 PM GMT+1

Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Precigen, Inc. (NASDAQ:PGEN) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in the biotech space. There will always be biotech […]

Insider Monkey 2 days ago

PGEN
FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the US Food and Drug Administration (FDA) has accepted the company's biologics license application (BLA) for PRGN-2012 (nonproprietary name: zopapogene imadenovec†), an investigational AdenoVerse® gene therapy for the treatment of adults with recurrent respiratory papillomatosis (RRP). The FDA granted priority review to

PR Newswire 6 days ago

PGEN
Exploring 3 High Growth Tech Stocks in the United States

The United States market has been flat in the last week, but it has risen by 20% over the past 12 months, with earnings expected to grow by 15% per annum in the coming years. In this environment, identifying high growth tech stocks that can capitalize on these trends involves looking for companies with strong innovation potential and robust business models.

Simply Wall St. 21 days ago

PGEN

TRIP

TVTX
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced highlights for the upcoming company presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 AM PT/12:00 PM ET. Participants may view details for Precigen's company presentation at Precigen's website in the Events & Presentations section at investors.precigen.com/events-pre

PR Newswire last month

PGEN
Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 AM PT in San Francisco, California.

PR Newswire last month

PGEN
Exploring 3 Prominent High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has dropped 2.6%, yet it remains up by 23% over the past year with earnings anticipated to grow by 15% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies with strong innovation potential and robust financial health that can thrive even amidst short-term market fluctuations.

Simply Wall St. last month

HALO

GDRX

PGEN
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the completion of the rolling submission for a biologics license application (BLA) to the US Food and Drug Administration (FDA) for PRGN-2012 (INN: zopapogene imadenovec†) for the treatment of adult patients with recurrent respiratory papillomatosis (RRP). The submission is in the initial 60 day review period, during wh

PR Newswire 2 months ago

PGEN
Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement. Precigen anticipates gross proceeds from the private placement of $79.0 million before deducting offering expenses. In addition, the investors will h

PR Newswire 2 months ago

PGEN
Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86%

We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...

Simply Wall St. 3 months ago

PGEN
Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2024 financial results and business updates.

PR Newswire 3 months ago

PGEN
Precigen to Participate in the Stifel 2024 Healthcare Conference

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat on Tuesday, November 19, 2024 from 10:55 to 11:25 AM ET at the Stifel 2024 Healthcare Conference taking place November 18 to 19, 2024 in New York.

PR Newswire 3 months ago

PGEN
High Growth Tech Stocks To Watch In October 2024

Over the last 7 days, the United States market has dropped by 1.0%, yet it has seen a substantial rise of 38% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability to capitalize on these promising earnings projections.

Simply Wall St. 4 months ago

PGEN

HEAR

TSVT
Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat on Wednesday, September 18, 2024 from 9:45 to 10:15 AM ET at the 2024 Cantor Global Healthcare Conference taking place September 17 to 19, 2024 in New York.

PR Newswire 5 months ago

PGEN
While institutions own 26% of Precigen, Inc. (NASDAQ:PGEN), private equity firms are its largest shareholders with 43% ownership

Key Insights Significant control over Precigen by private equity firms implies that the general public has more power...

Simply Wall St. 5 months ago

PGEN
Precigen Second Quarter 2024 Earnings: Misses Expectations

Precigen ( NASDAQ:PGEN ) Second Quarter 2024 Results Key Financial Results Net loss: US$58.8m (loss widened by 189...

Simply Wall St. 6 months ago

PGEN
Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2024 financial results and business updates.

PR Newswire 6 months ago

PGEN
Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2024 financial results and provide business updates on Wednesday, August 14, 2024. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update.

PR Newswire 6 months ago

PGEN
Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 35,294,118 shares of its common stock at a public offering price of $0.85 per share. Precigen has also granted the underwriters a 30-day option to purchase up to an additional 5,294,117 shares of its common stock. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $30.0 million, excluding any exerc

PR Newswire 6 months ago

PGEN
Precigen Announces Proposed $30 Million Public Offering of Common Stock

Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced a $30.0 million underwritten public offering of its common stock. In addition, Precigen intends to grant the underwriters a 30-day option to purchase up to an additional $4.5 million of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering. All of the shares in the proposed offering are to be s

PR Newswire 6 months ago

PGEN
Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced a strategic reprioritization of the Company's clinical portfolio and streamlining of resources, including a reduction of over 20% of its workforce, to focus on potential commercialization of the PRGN-2012 AdenoVerse® gene therapy for the treatment of recurrent respiratory papillomatosis (RRP).

PR Newswire 6 months ago

PGEN

Performance Overview

Return	I5X.F	S&P 500
YTD	+141.38%	-0.54%
1-Year	+15.03%	+13.87%
3-Year	-16.84%	+34.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Precigen, Inc. (I5X.F)

Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Exploring 3 High Growth Tech Stocks in the United States

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Exploring 3 Prominent High Growth Tech Stocks In The United States

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86%

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Precigen to Participate in the Stifel 2024 Healthcare Conference

High Growth Tech Stocks To Watch In October 2024

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

While institutions own 26% of Precigen, Inc. (NASDAQ:PGEN), private equity firms are its largest shareholders with 43% ownership

Precigen Second Quarter 2024 Earnings: Misses Expectations

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Performance Overview